Undiscovered European Gems with Promising Potential for March 2025

Amidst the backdrop of global trade uncertainties and economic adjustments, European markets have shown resilience, with mixed performances across major indices like Germany's DAX and France's CAC 40. As the European Central Bank navigates inflationary pressures and potential trade impacts, investors may find opportunities in small-cap stocks that are well-positioned to capitalize on regional economic shifts and strategic spending initiatives.

Top 10 Undiscovered Gems With Strong Fundamentals In Europe

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Ovostar Union	0.01%	10.19%	49.85%	★★★★★★
Mirbud	16.01%	27.19%	26.48%	★★★★★★
Bahnhof	NA	8.39%	14.20%	★★★★★★
La Forestière Equatoriale	NA	-58.49%	45.78%	★★★★★★
Moury Construct	2.93%	10.28%	30.93%	★★★★★☆
HOMAG Group	NA	-31.14%	23.43%	★★★★★☆
Flügger group	20.98%	3.24%	-29.82%	★★★★★☆
Sparta	NA	-5.54%	-15.40%	★★★★★☆
ABG Sundal Collier Holding	0.61%	-1.57%	-8.96%	★★★★☆☆
Practic	NA	3.63%	6.85%	★★★★☆☆

Click here to see the full list of 368 stocks from our European Undiscovered Gems With Strong Fundamentals screener.

Here's a peek at a few of the choices from the screener.

Faes Farma (BME:FAE)

Simply Wall St Value Rating: ★★★★★☆

Overview: Faes Farma, S.A. is involved in the research, development, production, and marketing of pharmaceutical and healthcare products as well as raw materials on a global scale, with a market cap of approximately €1.08 billion.

Operations: Faes Farma generates revenue primarily from its Pharmaceutical Products segment, contributing €457.80 million, and the Nutrition and Animal Health segment, which adds €52.30 million.

Faes Farma, a nimble player in the pharmaceuticals sector, has seen its earnings grow by 21.2% over the past year, outpacing the industry's 20.9%. With net income rising to €111.36 million from €91.9 million last year and revenue climbing to €510.04 million from €473.09 million, it’s clear they’re on an upward trajectory despite a debt-to-equity ratio increase from 3.2% to 6.9% over five years. Trading at nearly 13% below estimated fair value and with more cash than total debt, Faes Farma seems well-positioned for future challenges despite forecasts of a potential earnings decline averaging 6.3% annually over the next three years.

• Click here to discover the nuances of Faes Farma with our detailed analytical health report.

• Understand Faes Farma's track record by examining our Past report.

Savencia (ENXTPA:SAVE)

Simply Wall St Value Rating: ★★★★★★

Overview: Savencia SA is a company engaged in the production, distribution, and marketing of dairy and cheese products across France, the rest of Europe, and internationally with a market capitalization of approximately €748.93 million.

Operations: Savencia generates revenue primarily through the production, distribution, and marketing of dairy and cheese products. The company's net profit margin is 3.5%, reflecting its ability to manage costs relative to its revenue streams effectively.

Savencia, a notable player in the European food sector, reported impressive earnings growth of 10.9% last year, outpacing the industry average. The company's net debt to equity ratio stands at a satisfactory 24.9%, showing improved financial health as it dropped from 88.6% over five years. With high-quality past earnings and well-covered interest payments (9.4x EBIT), Savencia seems poised for stability and potential growth, especially with forecasted annual earnings growth of 5.95%. Recent financials reveal revenue rose to €7.14 billion from €6.79 billion, while net income increased to €107 million from €96.5 million last year.

• Click here and access our complete health analysis report to understand the dynamics of Savencia.

• Gain insights into Savencia's historical performance by reviewing our past performance report.

Astarta Holding (WSE:AST)

Simply Wall St Value Rating: ★★★★★★

Overview: ASTARTA Holding N.V. operates in sugar production, crop growing, soybean processing, and cattle farming across Ukraine and internationally, with a market capitalization of PLN 1.31 billion.

Operations: The company's primary revenue streams include agriculture (UAH 17.76 billion), sugar production (UAH 9.50 billion), and soybean processing (UAH 4.44 billion). Cattle farming contributes UAH 2.08 billion to the total revenue, highlighting its diverse agricultural operations.

Astarta Holding, a smaller player in the European market, has seen its debt to equity ratio improve significantly from 39.8% to 7.8% over five years, reflecting prudent financial management. Despite recent share price volatility, the company trades at nearly 93% below estimated fair value, suggesting potential undervaluation. Astarta's profitability is evident with interest payments well covered by EBIT at 4.1x coverage and earnings growth of 50.9%, outpacing the food industry's average of 28.7%. However, a notable one-off gain of UAH823M influenced recent results and future earnings are forecasted to decrease by an average of 32%.

• Get an in-depth perspective on Astarta Holding's performance by reading our health report here.

• Review our historical performance report to gain insights into Astarta Holding's's past performance.

Taking Advantage

• Click through to start exploring the rest of the 365 European Undiscovered Gems With Strong Fundamentals now.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com